Emergence Therapeutics strengthens leadership team with the appointment of Hatem Azim as Chief Medical Officer

Duisburg, Germany, 7 June 2022. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (“CMO”), as of 6 June 2022.

Dr. Hatem Azim joins Emergence Therapeutics from Pierre Fabre, a French multinational pharmaceutical company where he was Head of Oncology Early Clinical Development. In this role he was responsible for strategic clinical drug development and management of immuno-oncology and ADC research projects. Prior to this, Dr. Azim held the role of Vice President, Head of Clinical Development at Innate Pharma in France.

Dr. Azim holds a Medical Degree from Cairo University, a Master’s degree in Oncology from the University of Newcastle Upon Tyne and a PhD from the Université Libre De Bruxelles.  He is a Breast Cancer Medical Oncologist with strong academic background, having worked for many years at Jules Bordet Institute in Brussels after finishing his oncology training. He is highly published with more than 130 research papers and 10 book chapters. Hatem has served as member of several international guideline committees and has been invited as faculty member on numerous occasions including at the annual conferences of the European Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO). He was previously awarded the ASCO Merit Award and the University of Padova Breast Cancer Award in recognition of his work in the oncology field.

Jack Elands, CEO of Emergence Therapeutics, commented: “I am delighted to welcome Hatem to Emergence as our Chief Medical Officer. His leadership experience and expertise in clinical drug development will be instrumental in executing Emergence’s clinical strategy for ETx-22, our novel ADC targeting Nectin-4, as well as our broader strategy to become a dominant ADC developer.”

Hatem Azim commented: “Emergence Therapeutics is on the frontier of developing novel, highly selective ADCs for the treatment of hard-to-treat cancers. I’m very excited to join at this critical and exciting phase and look forward to joining the senior leadership team to help further advance ETx-22’s clinical development and future programs.”

– ENDS –

For more information, please contact:

Emergence Therapeutics

Dr. Jack Elands, Chief Executive Officer

Tel: +33 6 38 35 70 08

Consilium Strategic Communications

Chris Gardner, Maya Bennison

Email: Emergence@consilium-comms.com

Tel: +44 (0)20 3709 5813

 

About Emergence Therapeutics

Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as an ADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Emergence Therapeutics is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need. Emergence Therapeutics is based in Duisburg, Germany with a subsidiary in Marseille, France. For more information, please visit:

www.emergencetx.com

Latest News

07/06/2022

Emergence Therapeutics strengthens leadership team with the appointment of Hatem Azim as Chief Medical Officer

Duisburg, Germany, 7 June 2022. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (“CMO”), as of 6 June 2022. Dr. Hatem Azim joins Emergence Therapeutics from Pierre Fabre, a...

View Article >
07/12/2021

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

Series A round led by Pontifax and includes new and existing investors Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity Strategy is to become a dominant ADC developer   Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment...

View Article >
05/10/2021

Emergence Therapeutics and Mablink Bioscience Enter into a Licensing Agreement to Develop Antibody Drug Conjugate as a potential cancer therapy

Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s proprietary PSARlink™ drug-linker technology. Duisburg, Germany, and Lyon, France, 5 October 2021. Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat cancers with high unmet needs and Mablink Bioscience S.A.S. a biotechnology company developing...

View Article >